

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## SoftMedx Healthcare Limited

京玖醫療健康有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 648)**

**(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;  
(2) RE-DESIGNATION OF DIRECTOR AND  
APPOINTMENT OF AUTHORISED REPRESENTATIVE;  
(3) RESIGNATION OF DIRECTORS; AND  
(4) CHANGE IN THE COMPOSITION OF THE BOARD COMMITTEES**

The Board announces that with effect from 1 August 2024:

- (i) Mr. Lin Pinzhuo has been (a) re-designated from an independent non-executive director to an executive director of the Company; (b) redesignated from the chairperson to a member of the nomination committee; and (c) appointed as an authorised representative of the Company and has resigned a member of the audit committee;
- (ii) Mr. Ngok Ho Wai has been appointed as an independent non-executive director of the Company, the chairperson of the nomination committee and a member of the audit committee, the remuneration committee and the risk management committee;
- (iii) Ms. Tang Cuihuen has been appointed as an independent non-executive director of the Company and a member of the audit committee;
- (vi) Mr. Yiu Chun Wing has been re-designated from a member to the chairperson of the remuneration committee;
- (v) Mr. Chng Wai Kwan has resigned as an executive director of the Company;
- (vi) Mr. Wang Jianguo has resigned as an executive director and an authorised representative of the Company and a member of the risk management committee; and
- (vii) Ms. Hu Xuezhen has resigned as an independent non-executive director of the Company, the chairperson of the remuneration committee and a member of the audit committee and the nomination committee.

## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “Board”) of directors of SoftMedx Healthcare Limited (the “Company”) is pleased to announce that (i) Mr. Ngok Ho Wai has been appointed as an independent non-executive director of the Company, the chairperson of the nomination committee and a member of the audit committee, the remuneration committee and the risk management committee of the Board; and (ii) Ms. Tang Cuihuan has been appointed as an independent non-executive director of the Company and a member of the audit committee with effect from 1 August 2024. Biographical details of Mr. Ngok and Ms. Tang are set out as follows:

### **Mr. Ngok Ho Wai**

Mr. Ngok, aged 55, is a seasoned banker with extensive experience in the banking industry, specialising in corporate and investment banking with a focus on the Greater Bay Area, and has held managerial roles in a number of renowned banks in Hong Kong, where he established credit procedures and loan administration policies for small and medium-sized enterprises. Mr. Ngok also has substantial expertise in internal audit and is currently the vice president of the Association of Chinese Internal Auditors. In addition, Mr. Ngok is (i) the vice president of the Hong Kong Greater China SME Alliance Association, (ii) an advisory board member of Hong Kong Young Financial Planners’ Association and (iii) a committee member of the Hong Kong New Territories District Adviser Alumni Association. Mr. Ngok is a fellow member of the Hong Kong Institute of Certified Public Accountants and a member of CPA Australia. He holds a bachelor’s degree in social science with honours from The Chinese University of Hong Kong, a master’s degree in accounting from Curtin University (formerly known as Curtin University of Technology) and a master’s degree in laws with specialisation in international and commercial law from The University of Greenwich.

Mr. Ngok is currently an independent non-executive director of Tai Kam Holdings Limited (stock code: 8321), Times Universal Group Holdings Ltd. (stock code: 2310) and Basetrophy Group Holdings Limited (stock code: 8460), the issued shares of which are all listed on The Stock Exchange of Hong Kong Limited. Save as disclosed herein, Mr. Ngok does not hold other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas during the three years preceding the date of his appointment.

Mr. Ngok (i) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company; (ii) is not interested in or deemed to be interested in any share, underlying share or debenture of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”); (iii) does not hold any other position in the Company or its subsidiaries and (iv) has confirmed his independence as set out in Rule 3.13 of the The Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Mr. Ngok has not entered into a service contract with the Company and will hold office until the next annual general meeting of the Company and thereafter subject to retirement by rotation and re-election once every three years at an annual general meeting of the Company in accordance with its articles of association. Mr. Ngok is entitled to a director’s fee of HK\$120,000 per annum as determined by reference to his duties and responsibilities with the Company. Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter in relation to the appointment of Mr. Ngok that needs to be brought to the attention of the shareholders of the Company.

### **Ms. Tang Cuihuan**

Ms. Tang, aged 43, has over 20 years of experience in corporate management and treasury and financial management in the healthcare and related industries. Over the years, she has taken roles in corporate management, reforming and merging companies, business development and synergic collaboration in a number of companies. Ms. Tang holds a university diploma in computerised accounting from Guangdong Polytechnic of Science and Technology.

Ms. Tang (i) has not held any directorship in any public listed company in Hong Kong or overseas in the last three years preceding the date of this announcement; (ii) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company; (iii) is not interested in or

deemed to be interested in any share, underlying share or debenture of the Company within the meaning of the SFO; (iv) does not hold any other position in the Company or its subsidiaries; and (iv) has confirmed her independence as set out in Rule 3.13 of the Listing Rules.

Ms. Tang has not entered into a service contract with the Company and will hold office until the next annual general meeting of the Company and thereafter subject to retirement by rotation and re-election once every three years at an annual general meeting of the Company in accordance with its articles of association. Ms. Tang is entitled to a director's fee of HK\$96,000 per annum as determined by reference to her duties and responsibilities with the Company. Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter in relation to the appointment of Ms. Tang that needs to be brought to the attention of the shareholders of the Company.

The Board warmly welcomes Mr. Ngok and Ms. Tang as directors.

## **RE-DESIGNATION OF DIRECTOR AND APPOINTMENT OF AUTHORISED REPRESENTATIVE**

The Board announces that with effect from 1 August 2024, Mr. Yiu Chun Wing has been re-designated from a member to the chairperson of the remuneration committee of the Board and Mr. Lin Pinzhuo has been (i) re-designated from an independent non-executive director to an executive director of the Company; (ii) redesignated from the chairperson to a member of the nomination committee; and (iii) appointed as the authorised representative of the Company and has resigned as a member of the audit committee.

Mr. Lin, aged 58, has 30 years of experience and sophisticated background in product commercialisation, production, business development and marketing. Prior to joining the Company, he has held management positions in a number of medical and technology companies, specialising in equipment supply chain management, logistics management, information system management and planning and equipment integration and customisation. Mr. Lin graduated from Shenzhen University with specialization in electronics and computer science. Mr. Lin was appointed as an independent non-executive director of the Company in February 2023.

Mr. Lin (i) has not held any directorship in any other public listed company in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company; (ii) is not interested in or deemed to be interested in any share, underlying share or debenture of the Company within the meaning of the SFO; and (iv) does not hold any other position in the Company or its subsidiaries. Mr. Lin is entitled to a director's fee of HK\$120,000 per annum as determined by reference to his duties and responsibilities with the Company.

Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter in relation to the re-designation of Mr. Lin that needs to be brought to the attention of the shareholders of the Company

## **RESIGNATION OF DIRECTORS**

The Board also announces that with effect from 1 August 2024, Mr. Cheung Wai Kwan has resigned as an executive director of the Company; Mr. Wang Jianguo has resigned as an executive director of the Company and a member of the risk management committee of the Board; and Ms. Hu Xuezheng has resigned as an independent non-executive director, the chairperson of the remuneration committee, a member of the audit committee and the nomination committee of the Board as they wish to devote more time to their personal matters and commitments which require more of their dedication and time.

Each of Mr. Cheung, Mr. Wang and Ms. Hu has confirmed that he/she has no disagreement with the Board and there is no matter relating to his/her resignation which needs to be brought to the attention of the shareholders of the Company.

The Board wishes to express sincere gratitude to Mr. Cheung, Mr. Wang and Ms. Hu for their valuable contribution to the Company during their tenure of office.

## GENERAL

Trading in the shares of the Company will continue to be suspended pending fulfilment of the resumption conditions. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

For and on behalf of the Board of  
**SoftMedx Healthcare Limited**  
Lam Sung Him Gaston  
*Company Secretary*

Hong Kong, 1 August 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. Lin Pinzhuo as executive director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.*